Efficacy and immunomodulatory effect of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancer: preclinical and clinical analysis - PubMed
3 days ago
- #CAR-T therapy
- #Digestive tract cancer
- #Immunomodulation
- Claudin18.2-specific IL-7/XCL1 armored CAR-T cells (ExCAR-T/RD07) show efficacy in digestive tract cancer (DTC).
- Preclinical results indicate durable suppression of DTC growth by activating CAR-T and endogenous immune responses.
- Clinical trial (10 patients) demonstrated RD07 was well-tolerated, with 70% showing tumor regression (100% DCR in moderate/high CLDN18.2 cases).
- Single-cell RNA sequencing revealed RD07 remodels the tumor microenvironment (TME) and enhances cytotoxic activity.
- RD07 represents an innovative CAR-T therapy combining antitumor effects and TME modulation for DTC.